Adenocarcinoma: Difference between revisions

Jump to navigation Jump to search
 
(12 intermediate revisions by one other user not shown)
Line 29: Line 29:
* [[Cervical cancer]]
* [[Cervical cancer]]
* [[Vaginal cancer]]
* [[Vaginal cancer]]
===Gross Pathology===
<gallery>
Image:gastcarc_enface.jpg|This cancer presented in a 40-year-old woman complaining of abdominal pain. Endoscopically it was a "very suspicious" ulcer. Biopsy showed diffusely infiltrating signet ring cell adenocarcinoma. These are gross photos of the subtotal gastrectomy specimen. The photo above is a seen face view of the ulcer. The pyloric margin is to the left. The ulcer is on the lesser curvature.
Image:Gastcarc xsec.jpg|This is a longitudinal section cut in the plane of the lesser curvature. The pylorus is to the left. Note several prominent nodes of the lesser omentum; these contained metastatic cancer.
</gallery>


==Physical Examination==
==Physical Examination==
Line 132: Line 125:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Diseases
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Risk factors/Epidemiology
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | History
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Clinical Findings
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Gross Pathology
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Histopathology
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Immunohistochemistry
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Lab Findings
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Imaging
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Metastatic Potential
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Gold Standard
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Additional Findings
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Gastric Cancer
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Gastric Cancer
Line 186: Line 193:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Appendix Cancer
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Appendix Cancer
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Diseases
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Risk factors/Epidemiology
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | History
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Clinical Findings
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Gross Pathology
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Histopathology
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Immunohistochemistry
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Lab Findings
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Imaging
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Metastatic Potential
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Gold Standard
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Additional Findings
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Gallbladder Cancer
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Anal Cancer
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 223: Line 270:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Endometrial Cancer
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Vulvar Cancer
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Diseases
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Risk factors/Epidemiology
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | History
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Clinical Findings
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Gross Pathology
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Histopathology
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Immunohistochemistry
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Lab Findings
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Imaging
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Metastatic Potential
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Gold Standard
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Additional Findings
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Prostate Cancer
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Prostate Cancer
Line 237: Line 324:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Bladder Cancer
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Testicular Cancer
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Urinary Bladder Cancer
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Urethral Cancer
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Metastatic Cancer
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | Cancer of Unknown Primary
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Latest revision as of 17:20, 27 May 2019

Template:DiseaseDisorder infobox

WikiDoc Resources for Adenocarcinoma

Articles

Most recent articles on Adenocarcinoma

Most cited articles on Adenocarcinoma

Review articles on Adenocarcinoma

Articles on Adenocarcinoma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Adenocarcinoma

Images of Adenocarcinoma

Photos of Adenocarcinoma

Podcasts & MP3s on Adenocarcinoma

Videos on Adenocarcinoma

Evidence Based Medicine

Cochrane Collaboration on Adenocarcinoma

Bandolier on Adenocarcinoma

TRIP on Adenocarcinoma

Clinical Trials

Ongoing Trials on Adenocarcinoma at Clinical Trials.gov

Trial results on Adenocarcinoma

Clinical Trials on Adenocarcinoma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Adenocarcinoma

NICE Guidance on Adenocarcinoma

NHS PRODIGY Guidance

FDA on Adenocarcinoma

CDC on Adenocarcinoma

Books

Books on Adenocarcinoma

News

Adenocarcinoma in the news

Be alerted to news on Adenocarcinoma

News trends on Adenocarcinoma

Commentary

Blogs on Adenocarcinoma

Definitions

Definitions of Adenocarcinoma

Patient Resources / Community

Patient resources on Adenocarcinoma

Discussion groups on Adenocarcinoma

Patient Handouts on Adenocarcinoma

Directions to Hospitals Treating Adenocarcinoma

Risk calculators and risk factors for Adenocarcinoma

Healthcare Provider Resources

Symptoms of Adenocarcinoma

Causes & Risk Factors for Adenocarcinoma

Diagnostic studies for Adenocarcinoma

Treatment of Adenocarcinoma

Continuing Medical Education (CME)

CME Programs on Adenocarcinoma

International

Adenocarcinoma en Espanol

Adenocarcinoma en Francais

Business

Adenocarcinoma in the Marketplace

Patents on Adenocarcinoma

Experimental / Informatics

List of terms related to Adenocarcinoma


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Adenocarcinoma is a form of carcinoma that originates in glandular tissue. To be classified as adenocarcinoma, the cells do not necessarily need to be part of a gland, as long as they have secretory properties. This form of carcinoma can occur in some higher mammals, including humans.[1] The term adenocarcinoma is derived from 'adeno' meaning 'pertaining to a gland' and 'carcinoma', which describes a cancer that has developed in the epithelial cells. It can first present as an adenoma (a glandular tumor that is benign).

Pathophysiology

Examples of tissues where adenocarcinomas may arise:

Physical Examination

Adenocarcinoma-In The Submandibular Salivary Glands


Differential Diagnosis

Diseases Risk factors/Epidemiology History Clinical Findings Gross Pathology Histopathology Immunohistochemistry Lab Findings Imaging Metastatic Potential Gold Standard Additional Findings
Head & Neck Cancer
Paranasal Sinus Cancer
Lung Cancer
Breast Cancer
Esophageal Cancer
Diseases Risk factors/Epidemiology History Clinical Findings Gross Pathology Histopathology Immunohistochemistry Lab Findings Imaging Metastatic Potential Gold Standard Additional Findings
Gastric Cancer
Pancreatic Cancer
Small Bowel Cancer
Colorectal Cancer
Appendix Cancer
Diseases Risk factors/Epidemiology History Clinical Findings Gross Pathology Histopathology Immunohistochemistry Lab Findings Imaging Metastatic Potential Gold Standard Additional Findings
Gallbladder Cancer
Anal Cancer
Cervical Cancer
Vaginal Cancer
Endometrial Cancer
Vulvar Cancer
Diseases Risk factors/Epidemiology History Clinical Findings Gross Pathology Histopathology Immunohistochemistry Lab Findings Imaging Metastatic Potential Gold Standard Additional Findings
Prostate Cancer
Testicular Cancer
Urinary Bladder Cancer
Urethral Cancer
Metastatic Cancer
Cancer of Unknown Primary

References

  1. Fauquier, D.A., Gulland, F.M.D.,(Marine Mammal Center), Haulena, M., Spraker, T., ‘’Biliary adenocarcinoma in a stranded Northern elephant seal (‘’Mirounga angustirortsis’‘)’‘, Journal of Wildlife Diseases 39(3):723-726 (2003)

Template:Epithelial neoplasms

de:Adenokarzinom gl:Adenocarcinoma nl:Adenocarcinoom


Template:WikiDoc Sources